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{Department of Hematology, Division of Experimental Hematology, St. Jude Children’s Research Hospital, Memphis, TennesseeABSTRACT Human normal and sickle red blood cells (RBCs) adhere with high affinity to the alpha5 chain of laminin (LAMA5)
via the basal cell adhesion molecule/Lutheran (BCAM/Lu) receptor, which is implicated in vasoocclusive episodes in sickle cell
disease and activated through the cyclic adenosine monophosphate (cAMP) signaling pathway. However, the effect of the
cAMP pathway on the expression of active BCAM/Lu receptors at the single-molecule level is unknown. We established an
in vitro technique, based on atomic force microscopy, which enables detection of single BCAM/Lu proteins on the RBC surface
and measures the unbinding force between BCAM/Lu and LAMA5. We showed that the expression of active BCAM/Lu receptors
is higher in homozygous sickle RBCs (SS-RBCs) than normal RBCs and that it is critically dependent on the cAMP signaling
pathway on both normal and SS-RBCs. Of importance, we illustrated that A-kinase anchoring proteins are crucial for BCAM/
Lu receptor activation. Furthermore, we found that SS-RBCs from hydroxyurea-treated patients show a lower expression of
active BCAM/Lu receptors, a lower unbinding force to LAMA5, and insignificant stimulation by epinephrine as compared to
SS-RBCs from untreated patients. To our knowledge, these findings may lead to novel antiadhesive targets for vasoocclusive
episodes in sickle cell disease.INTRODUCTIONRed blood cells (RBCs) express several surface adhesion
receptors known to modulate cellular physiology (1,2). In
sickle cell disease (SCD) (3,4), cytoadherence of RBCs to
the alpha5 chain of endothelial laminin (LAMA5) via the
basal cell adhesion molecule/Lutheran (BCAM/Lu) recep-
tor is thought to be a major contributor to and possibly the
primary cause of vasoocclusive episodes (VOEs) (5,6). On
normal and homozygous sickle RBCs (SS-RBCs), the acti-
vation of adhesion receptors can be modulated by hormones
such as epinephrine (7,8), pharmaceutical drugs such as hy-
droxyurea (HU) (9,10), and other biochemical stimuli (11).
Because SCD patients have extensive endothelial damage
(12) and elevated plasma levels of laminin (13), RBC adhe-
sion studies have focused on the specific interaction
between BCAM/Lu and LAMA5, a component of the
subendothelial matrix (14–16). Although it is known that
this interaction is mediated by cyclic adenosine monophos-
phate (cAMP) (8), the effects of the cAMP signaling
pathway on the expression of BCAM/Lu receptors and on
the interaction between BCAM/Lu and LAMA5 at the
single-molecule level are unknown. Furthermore, it is un-
known if scaffold or anchoring proteins, such as A-kinase
anchoring proteins (AKAPs) (17), play a role in BCAM/
Lu receptor activation. It is also unknown, at the single-
molecule level, if treatment with HU modulates BCAM/Submitted November 4, 2013, and accepted for publication February 3,
2014.
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0006-3495/14/03/1258/10 $2.00Lu receptor expression or modifies the strength of the
bond between BCAM/Lu and LAMA5.
In this work, we employed single-molecule atomic force
microscopy (AFM) (7,18,19) to quantitatively study the
modulation of BCAM/Lu expression on the membrane of
normal and SS-RBCs. Single-molecule AFM measures the
unbinding force between a specific ligand and its corre-
sponding receptor on a single cell with piconewton sensi-
tivity (20–23). We detected the unbinding force between
BCAM/Lu and LAMA5, which is interpreted as adhesive
force. The generated data are used to calculate the expres-
sion of active BCAM/Lu receptors on the RBC surface
and their spatial distribution on the membrane at high reso-
lution (~30 nm) (7,20,24).
Previous experimental approaches using flow adhesion as-
says (8) have shown that in SS-RBCs, the interaction between
BCAM/Lu and LAMA5 is strongly mediated by cAMP-
dependent protein kinase A (PKA) (8,15). Stimulation of
the b2-adrenergic receptor (b2-AR) (25,26) activates the
G-protein coupled receptor Gas, which stimulates adenylyl
cyclase (AC) (27). AC then catalyzes the conversion of
ATP to cAMP, resulting in PKA activation and ensuing
BCAM/Lu-laminin adhesion. Normal RBCs, however,
adhere minimally to the vascular endothelium (2) and their
response to stimulation by epinephrine or forskolin (FSK)
has not been detected by flow adhesion experiments (8).
Here, by using a single-molecule assay, we clearly detected
variability in the expression of BCAM/Lu on normal and
SS-RBCs as it is modulated by the cAMP signaling pathway.
It is currently unknown if the scaffold protein AKAPs
(17) play a role in BCAM/Lu receptor activation byhttp://dx.doi.org/10.1016/j.bpj.2014.02.001
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within RBCs. In other cell types, it has been found that
PKA activity is localized within the cell by attachment of
the PKA molecule to an AKAP. Specifically, a PKA tetra-
meric holoenzyme (28), consisting of two catalytic and
two regulatory subunits, binds to an AKAP via its regulatory
subunits. The resultant PKA/AKAP complex is localized to
a unique subcellular domain due to the AKAP-specific
targeting domain (25,29). In this work, we showed that
AKAPs mediate the activation of BCAM/Lu by PKA in
RBCs, signifying that cAMP activates PKA locally, close
to the cell membrane.
Hillery et al. (9) first demonstrated that SS-RBCs from
patients receiving HU undergo a decrease in adhesion to
LAMA5. This finding was contrasted by another result
(30) showing that the expression of BCAM/Lu receptors
on SS-RBCs from HU-treated patients increased. A resolu-
tion to this conflicting evidence was offered by a recent
work, which demonstrated that the reduced adhesion of
SS-RBCs to LAMA5 is likely due to inhibition of BCAM/
Lu phosphorylation by HU (10). However, it is still unclear
if the lower adhesion is only due to the reduced expression
of active BCAM/Lu receptors as a result of inhibition of
BCAM/Lu phosphorylation, or if HU also affects the un-
binding force between BCAM/Lu and LAMA5. In our
experiments, we measured the expression and unbinding
force to LAMA5 of active BCAM/Lu receptors on SS-
RBCs from untreated and HU-treated patients. We found
that both the expression and adhesive force of active
BCAM/Lu molecules is decreased in HU-treated patients.
These data demonstrate a very beneficial effect of HU in
reducing the propensity of SS-RBCs to adhere to LAMA5.
In summary, we employed single-molecule AFM to
investigate interactions between RBCs and the endothelium,
and their regulation via cAMP. We quantified cAMP-depen-
dent modulation of active BCAM/Lu receptor expression in
normal and SS-RBCs. To our knowledge, we are first to
demonstrate that AKAPs are crucial for the activation of
BCAM/Lu receptors. Finally, we showed that HU treatment
results in decreased erythrocyte adhesion to the endothelium
due to lower expression of BCAM/Lu receptors and lower
binding forces between BCAM/Lu and LAMA5.METHODS
Patients and blood samples
Homozygous SCD patients (SS) at steady state, and age-/race-matched
healthy volunteers at least 18 years of age were eligible to participate in
this study, which was approved by the Institutional Review Boards of the
UCONN Health Center and UCONN-Storrs. Individuals with SCD were
eligible to participate if they had not been transfused in R3 months and
were not having an acute VOE, suggesting a phenotype of milder severity.
A complete blood count test was obtained for each patient. The untreated
patients averaged HbF concentrations of 9.6 5 4.0% (range: 0%–18.2%),
whereas HU-treated patients averaged 34.1% (range: 18.1%–56.1%). Retic-
ulocyte percentages averaged 10.8 5 2.0% (range: 4.2%–15.7%) for un-treated patients and 4.1 5 0.9% (range: 2.3%–6.7%) for HU-treated
patients. Healthy volunteers were eligible to participate if they did not
have a blood disorder or hemoglobinopathy, which was confirmed by
screening blood samples via hemoglobin electrophoresis. Experiments
were performed using fresh-drawn, heparin-anticoagulated venous blood.Red blood cell preparation
Whole blood was centrifuged at 500 g for 10 min at 4C to isolate RBCs.
The buffy coat was aspirated and discarded. RBCs were washed 3 with
Alsever’s solution. RBCs were immobilized by incubation on a poly-l-
lysine-coated glass petri dish for 10 min at 37C and unattached RBCs
were removed by rinsing.Reagents
Human laminin subunit alpha-5 (LAMA5) was obtained from
MyBioSource (San Diego, CA), St-Ht31 inhibitor peptide and St-Ht31P
control peptide (reconstituted in Alsever’s solution) were obtained from
Promega (Madison, WI). Alsever’s solution, FSK (Coleus forskohlii)
(reconstituted in DMSO), Rp-Adenosine 30,50-cyclic monophosphoro-
thioate triethylammonium salt (Rp-cAMPS; reconstituted in DMSO), KT-
5720 (reconstituted in methanol), epinephrine (reconstituted in Alsever’s
solution), bovine serum albumin (BSA; reconstituted in PBS) were pur-
chased from Sigma Aldrich (St. Louis, MO).Preparation of LAMA5 probes
Silicon nitride cantilevers (Bruker Probes, Camarillo, CA) were silanized
with 2% v/v 3-aminopropyltriethoxysilane in acetone (10 min), and then
rinsed with deionized water and immersed in glutaraldehyde (0.5%,
30 min). Cantilevers were rinsed with deionized water, incubated in
LAMA5 solution (100 mg/mL, 30 min), rinsed again, and incubated in
BSA (100 mg/mL, 5 min) to block remaining aldehyde groups. Cantilevers
were stored at 4C and used within 48 h.AFM assays
Force-distance curves were recorded between laminin-functionalized
probes and BCAM/Lu receptors on the RBC surface (Fig. 1 A) using the
MFP-3D-BIO AFM (Asylum Research, Santa Barbara, CA). An unbinding
force is defined as the maximum rupture force associated with the force-
distance curve. A representative curve highlighting regions of the approach
and retraction cycle is shown in Fig. 1 B. On surface regions void of BCAM/
Lu receptors, we expected the unbinding force to be zero, although unbind-
ing forces are significantly higher in regions where the laminin-functional-
ized cantilever made contact with active BCAM/Lu receptors. Unbinding
forces were measured on 1 mm  1 mm areas of the RBC membrane with
a lateral resolution of 31.25 nm (1024 sampled sites per experiment). To
determine the spatial distribution of BCAM/Lu receptors on the RBC sur-
face, unbinding forces were plotted as a force map (see Fig. 1 D) using
MATLAB (The MathWorks, Natick, MA) in which the color of each square
indicates the magnitude of the corresponding unbinding force obtained
from an individual force-distance curve (7).
An inverted microscope (Zeiss Axiovert A1) was used to position the
AFM cantilever in contact with a chosen RBC (Fig. 1 C). Chosen RBCs
were <10 mm in diameter and exhibited a distinct biconcave shape, sug-
gesting RBC maturity. Experiments were performed in Alsever’s solution
at 37C, and biochemical modulators were added at least 30 min before
experiments (30 min: Epinephrine, FSK, KT-5720, Rp-cAMPS; 120 min:
St-Ht31, StHt31P). For each assay, three RBCs were tested from each sub-
ject’s blood. Values reporting N ¼ denote the number of unique donors per
condition and n ¼ denote the total number of tested cells. MeasurementsBiophysical Journal 106(6) 1258–1267
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FIGURE 1 Measurement of the frequency of
active BCAM/Lu surface receptors and the unbind-
ing force with LAMA5 on RBCs using AFM. (A)
AFM cantilever probe functionalized with
LAMA5. Illustration corresponds to the force curve
shown in (B). (B) Force curve obtained from exper-
iments highlighting regions of the approach and
withdrawal of the cantilever from the sample.
When LAMA5 attached to the AFM probe adheres
to a BCAM/Lu receptor on the cell, the force-
displacement curve exhibits an abrupt shift to
zero, which corresponds to the rupture force (red
curve). If there is no BCAM/Lu receptor at the
detection point and consequently no adhesive inter-
action, then the retraction curve is similar to the
black curve. Specific regions are as follows: (i)
No interaction between the tip and cell; (ii) Func-
tionalized cantilever deflects downward toward
the cell as a result of van der Waals forces; (iii)
Positive deflection of the cantilever due to repulsive
forces; (iv) Negative deflection of the cantilever tip
as a result of adhesion forces between the tip and
the cell. (C) Representative optical microscopy im-
age showing a human RBC and an AFM cantilever
probe. (D) Unbinding force maps of single normal
RBCs (i) in the absence and (ii) presence of bath
laminin to mask BCAM/Lu binding sites. (iii)
Unbinding force maps of single normal RBCs in
epinephrine (1 mM) show an increase in active
BCAM/Lu receptors. Scale bars, 250 nm. Color
scale as shown. (E) Frequency distributions of
measured unbinding forces fit with the Gaussian
model to obtain the average unbinding force and
(F) box-whisker plot of the collective frequency
of detected BCAM/Lu receptors on normal RBCs
per experimental condition. Data are presented as
median with max and min whiskers and the average
denoted as (þ).The n on the x axis indicates the
total number of mature RBCs analyzed in each
group, obtained from the following numbers of hu-
man subjects: – Bath laminin: 4 subjects; þ Bath
laminin, þ Epinephrine: 3 subjects. Significance
relative to – bath laminin is denoted as * such
that p< 0.05 and ** such that p< 0.005 (two-tailed
t-test). To see this figure in color, go online.
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constant of the employed cantilever was 30 pN/nm and the exact spring
constant value was obtained via a thermal noise-based method and used
in all calculations (31).Statistical methods
Values for the unbinding force between BCAM/Lu and LAMA5 are re-
ported as average 5 SD as determined by a frequency distribution fit
with the Gaussian model (GraphPad Prism). In the frequency (%) distribu-
tion, each bin contains the number of unbinding forces with values within
the bin’s range divided by the total number of sampled sites. We note that
the frequency of zero force points is not shown because it is much larger
than the frequency of nonzero force points and would obscure the graphs.
Collective frequency (%), denoted CF, is the frequency of active BCAM/
Lu surface receptors and is defined as the total number of all nonzero force
points, without respect to specific unbinding forces, divided by the total
number of sampled sites for each experimental condition. It is reported as
average 5 SE and is illustrated by box-whisker plots. The collective fre-Biophysical Journal 106(6) 1258–1267quency of active receptors was compared between groups using a one-
way analysis of variance (ANOVA) with the Tukey post hoc test, and
between two conditions using a two-tailed t-test. Results were considered
significant if p<0.05.RESULTS
Single-molecule measurement of active BCAM/Lu
receptors on normal RBCs
We first performed experiments on normal RBCs in
Alsever’s solution to determine the baseline frequency
( bath laminin) of active BCAM/Lu receptors and the un-
binding force of BCAM/Lu to LAMA5. Fig. 1 D(i) shows
representative BCAM/Lu-LAMA5 force maps with forces
detected between 21.66 and 65.39 pN. The frequency of
nonzero unbinding forces detected on normal RBCs is
Force Nanoscopy Detection of AKAPS on RBCs 1261shown in Fig. 1 E. By accumulating all of the nonzero
unbinding forces per cell we obtained the collective fre-
quency, as explained in the methods. The results, illustrated
using a box-whisker plot, show that unbinding forces were
detected in 3.31 5 0.67% of sampled sites (Fig. 1 F).
To determine the specificity of measured unbinding
forces, we repeated the experiments on normal samples
preincubated with laminin. As shown in Figs. 1 D(ii), F,
the CF of events detecting unbinding forces on RBCs prein-
cubated with laminin (þ bath laminin) was 0.895 0.21%,
which is significantly lower (p < 0.01) than the baseline
frequency ( bath laminin, CF: 3.31 5 0.67%). Recorded
unbinding forces likely reflected BCAM/Lu receptors that
were not bound by bath laminin. To establish that the assay
can detect variations in the number of active BCAM/Lu
receptors, we preincubated RBCs with epinephrine
(1 mM), a b-AR agonist known to increase BCAM/Lu
binding to LAMA5, and found that events were detected
in 10.27 5 2.02% of sampled sites, a significant increase
(p < 0.001) in the CF from baseline (Fig. 1 D(iii), F). Fre-
quency distributions (Fig. 1 E) show that although the
average unbinding force between BCAM/Lu and LAMA5
did not change in these experimental conditions, the fre-
quency of detected events changed significantly. Further-
more, the data in Fig. 1 F illustrate that the AFM-based
assay can detect differences in the collective frequency of
active BCAM/Lu receptors on normal RBCs at baseline
and preincubated with laminin or epinephrine.BCAM/Lu adhesion of normal RBCs to endothelial
laminin is PKA-dependent
Taking advantage of the high-resolution and high-sensitivity
of single-molecule AFM, we investigated changes in the
frequency of active BCAM/Lu receptors on normal and
SS-RBCs via pharmacologic modulation of the cAMP-
PKA pathway. First, we treated normal RBCs with FSK
(30 mM), a strong AC activator that stimulates cAMP pro-
duction, subsequently activating PKA. Compared to un-
treated RBCs, FSK-treated RBCs exhibited significantly
more unbinding events as shown by the frequency distribu-
tion and box-whisker plots (Fig. 2, A and C; CF: 18.19 5
4.68%; p < 0.001). The specificity of increased frequency
of binding between the functionalized tip and the RBC
was demonstrated by preincubating RBCs with human
BCAM antibody, which resulted in a very significant
decrease in the frequency of binding events (Fig. S1 in the
Supporting Material). Previous evidence suggests that the
interaction between BCAM/Lu and LAMA5 is stimulated
significantly by FSK in SS-RBCs but insignificantly in
normal RBCs (8). These studies used a FSK concentration
(80 mM) much higher than that currently used (30 mM).
To understand the discrepancy between ours and previous
results, we used the higher concentration of FSK employed
in the previous study (8). In this case, we found that theinteraction between BCAM/Lu and LAMA5 was stimulated
(data not shown; CF: 10.105 1.89%, N ¼ 3, n ¼ 9) signif-
icantly more than normal RBCs at baseline (p < 0.05),
albeit not significantly more than those treated with 30
mm FSK. It is possible that flow adhesion assays, which
measure the average adhesion of a large number of erythro-
cytes to a functionalized-substrate under flow-induced shear
stress, are not sensitive enough to detect increases in the
overall low adhesion of normal RBCs.
To quantify the effect of PKA inhibition on the frequency
of active BCAM/Lu receptors, we treated RBCs with
Rp-cAMPS (100 mM), a strong inhibitor of PKA activation
by cAMP. RBCs pretreated with Rp-cAMPS exhibited
fewer unbinding events (Fig. 2, B and C; CF: 1.17 5
0.47%) than normal RBCs at baseline. An apparent decrease
in the unbinding force following preincubation with Rp-
cAMPS compared to baseline results is statistically insignif-
icant. Next, we directly inhibited PKA using KT-5720
(1 mM) and recorded a decrease in the unbinding event
frequency (Fig. 2, B and C; CF: 2.16 5 0.41%), albeit not
as large as with Rp-cAMPS. Fig. 2 C shows a box-whisker
plot summarizing changes in the collective frequency of
active BCAM/Lu receptors on normal RBCs in response
to cAMP-dependent pathway modulation. It is clear that
there is a significant increase in the collective frequency
of active BCAM/Lu receptors resulting from 30 mM FSK,
demonstrating that our system can detect changes in the
adhesive properties of human RBCs in response to increases
in intracellular cAMP.SS-RBCs demonstrate greater PKA-dependence
of BCAM/Lu adhesion to endothelial laminin than
normal RBCs
After establishing our single-molecule AFM technique on
normal RBCs and confirming that we can detect differences
in the frequency of active BCAM/Lu in response to cAMP-
dependent pathway modulators, we applied the same exper-
imental approach to SS-RBCs. In agreement with previous
reports (2,8), we measured a significant increase in the fre-
quency of BCAM/Lu receptors on SS-RBCs (Fig. 3, A and
E; CF: 8.89 5 2.05%) as compared to normal RBCs (p <
0.01). Next, we quantified changes in the frequency of active
BCAM/Lu receptors on SS-RBCs in response to cAMP-
dependent pathway modulation. Following preincubation
with FSK (30 mM), we observed an increase in the CF
to 20.56 5 3.63% on SS-RBCs, which was significantly
greater than that measured at baseline (Fig. 3 E; p < 0.01)
and similar to that observed on normal RBCs (Fig. 3 B).
Of importance, when treated with Rp-cAMPS, the adhesion
level of SS-RBCs reduced to that of normal RBCs treated
with Rp-cAMPS. However, preincubation with KT-5720
(see Fig. 3 D) did not decrease the BCAM/Lu receptor
frequency on SS-RBCs to the adhesion level of normal
RBCs, but still significantly decreased below the baselineBiophysical Journal 106(6) 1258–1267
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FIGURE 2 Distribution of BCAM/Lu on normal
RBCs and unbinding force of BCAM/Lu to
LAMA5. (A) Unbinding force maps and corre-
sponding unbinding force frequency histograms
of normal RBCs measured at baseline and after
treatment with 30 mM FSK, and (B) measured in
the presence of the PKA inhibitors Rp-cAMPS
and KT-5720. (C) Box-whisker plot showing the
collective frequency of detected BCAM/Lu recep-
tors on normal RBCs for the biochemical modula-
tors indicated on the x axis, presented as in Fig. 1.
The n on the x axis indicates the total number of
mature RBCs analyzed in each group, obtained
from the following numbers of human subjects:
Baseline: 4 subjects; FSK (30 mM), Rp-cAMPS,
KT-5720: 3 subjects. Significance relative to base-
line is denoted as * such that p < 0.001 (ANOVA,
Tukey post hoc test). To see this figure in color, go
online.
1262 Maciaszek et al.measurement to 2.66 5 1.02% (Fig. 3 E; p < 0.05).
Frequency distributions illustrate that the response to
modulation of BCAM/Lu on SS-RBCs was analogous to
that on normal RBCs (Fig. 3, B–D). Furthermore, the col-
lective frequency of detected BCAM/Lu receptors was
highly sensitive to cAMP-dependent pathway modulators
(Fig. 3 E). Table 1 presents specific unbinding forces
(mean 5 SD) and collective frequencies (mean 5 SE) for
normal and SS-RBCs.AKAPs regulate BCAM/Lu adhesion
After establishing that our assay can detect cAMP-depen-
dent modulation of active BCAM/Lu receptors on normal
and SS-RBCs, we investigated the possibility of localized
BCAM/Lu activation via AKAPs (25,29). To detect the
presence of AKAPs on normal and SS-RBCs, cells were
treated with St-Ht31 peptide (5 mM), which inhibits bindingBiophysical Journal 106(6) 1258–1267of PKA to AKAPs. Our experiments revealed that following
pretreatment with St-Ht31, the CF of active BCAM/Lu
receptors decreased significantly in normal RBCs (Fig. 4,
A and B; CF: 5.71 5 1.23% to 1.63 5 0.39%; p < 0.05)
and in SS-RBCs (Fig. 4, C and D; CF: 7.19 5 1.42% to
2.02 5 0.37%; p < 0.005). As a negative control, RBCs
were pretreated with St-Ht31P control peptide (5 mM),
which did not alter the collective frequency of active
BCAM/Lu receptors in normal RBCs (Fig. 4 B; CF:
5.92 5 1.09%) or in SS-RBCs (Fig. 4 D; CF: 6.49 5
1.27%) as compared to baseline measurements. To ensure
that AKAP inhibition would block BCAM/Lu receptor acti-
vation, RBCs were treated with St-Ht31 (5 mM) and
subsequently with FSK (30 mM). On normal RBCs, the
CF of active BCAM/Lu receptors was measured to be
5.83 5 1.65% vs. 18.19 5 4.68% following only FSK
stimulation (Fig. 4 B; p < 0.005). Similarly, on SS-RBCs
the CF of active BCAM/Lu receptors was measured to be
A B
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FIGURE 3 Distribution of BCAM/Lu on SS-RBCs and unbinding force
of BCAM/Lu to LAMA5. (A) SS-RBCs show a significantly greater num-
ber of BCAM/Lu surface receptors than normal RBCs at baseline. Measure-
ment after treatment with (B) 30 mMFSK, (C) 100 mMRp-cAMPS, and (D)
1 mMKT-5720 indicate that SS-RBCs behave similar to normal RBCs upon
cAMP-PKA pathway modulation. (E) Box-whisker plot of the collective
frequency of detected BCAM/Lu receptors on SS-RBCs for the biochem-
ical modulators indicated on the x axis. The n on the x axis indicates the
total number of mature RBCs analyzed in each group, obtained from the
following numbers of human subjects: Baseline: 5 subjects; FSK
(30 mM), Rp-cAMPS, KT-5720: 4 subjects. Significance relative to baseline
is denoted as * such that p < 0.05 and ** such that p < 0.01 (ANOVA,
Tukey post hoc test). To see this figure in color, go online.
TABLE 1 Values for the specific unbinding force and
collective frequency of normal and SS-RBCs measured in
response to cAMP-PKA pathway modulation
Unbinding force (pN) Collective frequency (%)
Test condition Normal SS Normal SS
Baseline 38.95 7.28 40.05 8.18 3.315 0.667 8.895 2.05
þFSK
(30 mM)
38.15 8.71 38.45 9.11 18.25 4.68 20.65 3.63
þRp-cAMPS
(100 mM)
31.95 5.90 33.95 7.57 1.175 0.470 1.345 0.441
þKT-5720
(1 mM)
38.85 9.34 37.25 6.18 2.165 0.411 2.665 1.02
Force Nanoscopy Detection of AKAPS on RBCs 12636.575 1.60% in this case versus 19.635 3.44% following
only FSK stimulation (Fig. 4 D; p < 0.005). This indicates
the presence of AKAPs in the RBC membrane and suggests
their importance in the mediation of RBC cytoadherence to
the endothelium in both normal and SS-RBCs. Table 2 pre-
sents specific unbinding forces (mean5 SD) and collective
frequencies (mean 5 SE) for normal and SS-RBCs.HU decreases the frequency and the strength of
BCAM/Lu-dependent adhesion events on SS-
RBCs
HU is currently the only pharmacologic treatment to reduce
the frequency of VOEs in SCD, yet only two-thirds of pa-tients respond favorably to the drug (32). The drug has
been found to inhibit phosphorylation of BCAM/Lu recep-
tors and consequently to decrease SS-RBC adhesion to
laminin (9,10). Here, we investigated the quantitative effect
of HU treatment on the frequency of active BCAM/Lu
receptors and on the magnitude of the unbinding force
between BCAM/Lu and LAMA5, which could be another
reason for the reduced adhesion of SS-RBCs to laminin.
Our experiments showed for the first time, to our knowl-
edge, that SS-RBCs from HU-treated patients have a signif-
icantly lower frequency of active BCAM/Lu receptors than
SS-RBCs from untreated patients (Fig. 5 A; CF: 8.89 5
2.05% to 2.43 5 0.51%; p < 0.001). Of importance, we
also detected that the unbinding force between BCAM/Lu
and LAMA5 was lower on SS-RBCs from HU-treated
patients (Fig. 5 B; CF: 35.14 5 7.18 pN vs. 40.00 5 8.12
pN; p < 0.0001). Differences in the unbinding force of
BCAM/Lu and laminin resulting from HU treatment have
not previously been reported. Next, the physiologic implica-
tion of epinephrine-stimulated adhesion of HU-treated
SS-RBCs was studied. We treated SS-RBCs with epineph-
rine and found that for SS-RBCs from patients undergoing
HU-treatment, the frequency of BCAM/Lu did not increase
significantly. Fig. 5 C shows that although the CF of BCAM/
Lu receptors increased significantly following treatment
with epinephrine on both normal RBCs and untreated
SS-RBCs, there was no significant increase in HU-treated
SS-RBCs.DISCUSSION
In this work, we established a technique, based on AFM,
which enables the detection of single BCAM/Lu molecules
on the RBC surface and measures the unbinding force
between BCAM/Lu and LAMA5. The technique is used
to study the effect of the cAMP signaling pathway on the
activation of BCAM/Lu receptors at the single-molecule
level. Of importance, we demonstrate that AKAPs are
essential for BCAM/Lu receptor activation, and that the
collective frequency of BCAM/Lu receptors, present on
both the normal and SS-RBC membrane, is critically depen-
dent on the cAMP pathway. Finally, we found that SS-RBCsBiophysical Journal 106(6) 1258–1267
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FIGURE 4 Modulation of BCAM/Lu via
AKAPs on the RBC membrane. (A) Measurements
in 5 mM St-Ht31 inhibitor peptide show the pres-
ence of AKAPs on normal RBC membranes as
revealed by the reduction of the frequency of active
BCAM/Lu receptors. (B) Box-whisker plot of the
collective frequency of detected BCAM/Lu recep-
tors on normal RBCs for the biochemical modula-
tors indicated on the x axis, presented as in Fig. 1.
The n on the x axis indicates the total number of
mature RBCs analyzed in each group, obtained
from the following numbers of human subjects:
Baseline, St-Ht31: 5 subjects; St-Ht31P: 4 subjects;
St-Ht31 þ FSK (30 mM): 3 subjects. Significance
relative to baseline is denoted as * such that p <
0.05 and ** such that p < 0.005 (ANOVA, Tukey
post hoc test). (C) Measurements in 5 mM St-
Ht31 inhibitor peptide shows the presence of
AKAPs on SS-RBC membranes as revealed by
the reduction of active BCAM/Lu receptors. (D)
Box-whisker plot of the collective frequency of
detected BCAM/Lu receptors on SS-RBCs for the
biochemical modulators indicated on the x axis,
presented as in Fig. 1. The n on the x axis indicates
the total number of mature RBCs analyzed in each
group, obtained from the following numbers of
human subjects: Baseline, St-Ht31, St-Ht31P, St-
Ht31 þ FSK (30 mM): 4 subjects. Significance
denoted as in (B). To see this figure in color, go
online.
1264 Maciaszek et al.from HU-treated patients have a lower frequency of active
BCAM/Lu receptors than SS-RBCs from untreated patients,
and undergo insignificant stimulation by epinephrine. We
also demonstrated that the unbinding force between
BCAM/Lu and LAMA5 in HU-treated patients is lower
than in untreated patients.cAMP-dependent modulation of BCAM/Lu on
normal RBCs
We first determined how the frequency of active BCAM/Lu
receptors changes in response to cAMP signaling. FSKTABLE 2 Values for the specific unbinding force and
collective frequency measured to detect the presence of
AKAPs on normal and SS-RBCs
Unbinding force (pN) Collective frequency (%)
Test condition Normal SS Normal SS
Baseline 41.05 9.33 40.95 8.04 5.715 1.23 7.195 1.42
þSt-Ht31
(5 mM)
39.95 11.4 38.95 9.96 1.635 0.391 2.025 0.368
þSt-Ht31P
(5 mM)
40.15 6.61 45.65 5.58 5.925 1.09 6.495 1.27
þSt-Ht31
þ FSK
44.65 8.63 42.55 9.91 5.835 1.65 6.575 1.60
Biophysical Journal 106(6) 1258–1267activates AC, which raises levels of cAMP and subsequently
activates the cAMP-dependent pathway. Normal RBCs
treated with FSK (30 mM) showed an increase in the fre-
quency of active BCAM/Lu receptors significantly above
baseline, in accordance with established cAMP-dependent
pathway modulation. However, previous studies based on
flow adhesion assays showed that adhesion of normal
RBCs via BCAM/Lu is not mediated significantly by
FSK, likely due to low levels of intracellular cAMP (8). In
contrast, our results indicate that normal RBC adhesion to
LAMA5 via the BCAM/Lu receptor is significantly modu-
lated by the cAMP-dependent pathway. This difference is
due to two reasons. First, previous studies used a FSK con-
centration of 80 mM, which is >2 greater than the concen-
tration we initially employed (30 mM). When normal RBCs
were treated with 80 mM FSK, the frequency of active
BCAM/Lu receptors did not increase as significantly above
the baseline as in the case of 30 mM FSK. This suggests that
high concentrations of FSK may desensitize BCAM/Lu
to cAMP-dependent pathway signaling, as shown for the
ICAM-4 receptor on RBCs and signaling receptors on other
cell types (33–35). Second, because the adhesiveness of
normal RBCs is low, the high-sensitivity of AFM allows
for a more precise detection of active adhesion receptors
A B
C
FIGURE 5 Modulation of the collective frequency of BCAM/Lu recep-
tors on SS-RBCs from HU-treated patients. (A) SS-RBCs from HU-treated
patients (N ¼ 4, n ¼ 12) have a significantly lower frequency of BCAM/Lu
receptors than SS-RBCs from untreated patients (N ¼ 5, n ¼ 15) and
healthy subjects (N ¼ 4, n ¼ 12). (B) Normalized cumulative distribution
clearly shows significant shift in the unbinding force of BCAM/Lu and
laminin on SS-RBCs from HU-treated patients (t-test, p< 0.0001). (C) Pre-
incubation with epinephrine causes a significant increase in the collective
frequency of BCAM/Lu receptors on both normal RBCs (N ¼ 3, n ¼ 9)
and SS-RBCs from untreated patients (N ¼ 5, n ¼ 15) but not on SS-
RBCs from HU-treated patients (N ¼ 4, n ¼ 12). Significance is denoted
as * such that p < 0.05 and ** such that p < 0.005 as computed using
the t-test. To see this figure in color, go online.
Force Nanoscopy Detection of AKAPS on RBCs 1265than traditional flow adhesion assays. We also note that flow
adhesion assays did not detect adhesion of nonstimulated
normal RBCs to laminin (8,10).cAMP-dependent modulation of BCAM/Lu on SS-
RBCs
Although the pathway by which cAMP mediates BCAM/Lu
receptor activation is well-established, the possibility that
AKAPs are involved in the localization of cAMP close to
the RBC membrane has not been investigated. In the current
work, we used specific biochemical modulators to investi-
gate the subcellular targeting of the cAMP-dependent
PKA (28). PKA activity can be mediated by AKAPs, which
sequester PKA to specific subcellular sites through binding
to its regulatory subunits (25,29,36). Each AKAP contains
two classes of binding sites: an anchoring motif, which
binds to the regulatory subunit of PKA, and a targeting
domain, which directs the subcellular localization of the
PKA-AKAP complex through association with structural
proteins, membranes, or other cell elements (29). BCAM/
Lu-mediated SS-RBC adhesion to LAMA5 is activated by
the phosphorylation of serine 621 in the BCAM/Lu cyto-
plasmic domain, but this phosphorylation does not occur
as readily in normal RBCs (15). We conjecture that this isdue to the presence of more PKA-AKAP complexes in
SS-RBCs, and resultant AKAP assistance in the phosphory-
lation of BCAM/Lu on RBCs. Furthermore, because protein
activation is highly selective despite the high cAMP diffu-
sion constant of 270–280 mm2/s, it is likely that the cAMP
is compartmentalized (37,38) and has a basal effect on
normal RBCs, which only requires increases in cAMP
near the membrane. This may explain why we detected
modulation of BCAM/Lu via the cAMP-dependent pathway
despite low levels of cAMP in normal RBCs (8).HU reduces the adhesion of SS-RBCs via the
BCAM/Lu receptor
HU, a pharmacologic treatment for SCD VOEs, is known to
stimulate an increase in HbF (39,40) synthesis, and may also
alter RBC signaling (9,10,41). The drug has been found to
decrease SS-RBC adhesion to laminin (9,10), although it
increases BCAM/Lu surface expression (10,30). Hillery
et al. (9) first demonstrated that RBCs from SCD patients
receiving HU undergo a decrease in adhesion to laminin.
Recently, it was shown that although BCAM/Lu receptor
expression is increased on SS-RBCs from HU-treated
patients, SS-RBC adhesion to laminin is decreased because
of inhibition of cAMP phosphorylation (10,30). In our
experiments, we measured a lower frequency of active
BCAM/Lu receptors on SS-RBCs from HU-treated patients
versus SS-RBCs from untreated patients. In addition, AFM
measurements revealed a lower unbinding force between
BCAM/Lu on SS-RBCs from HU-treated patients with
LAMA5 as compared to untreated patients. The lower
unbinding forces between BCAM/Lu and LAMA5 in
conjunction with the lower frequency of active BCAM/Lu
receptors on SS-RBCs from HU-treated patients demon-
strate the beneficial effect of HU in reducing SS-RBC adher-
ence to LAMA5, a mechanism thought to be critical to VOE
genesis.
To determine the physiological implications of cAMP-
stimulated adhesion of HU-treated RBCs, we preincubated
SS-RBCs from untreated and HU-treated patients with
epinephrine, a hormone released during stress and known
to stimulate the b2-AR (7,8). Our results indicate that
epinephrine does not significantly increase the frequency
of active BCAM/Lu receptors on the surface of SS-RBCs
from HU-treated patients. Furthermore, because we did
not detect a difference in the unbinding force or the receptor
frequency, we conjecture that HU modifies the b2-AR
pathway thereby reducing the ability for epinephrine-stimu-
lation. Consistent with previous studies related to the pheno-
typic variability of SCD (8), we also found that the patient
response to epinephrine was variable.
A determinant of clinical phenotype in SCD is the
adhesive properties of RBCs, defined by the subcellular
density and distribution of adhesion receptors, and the
unbinding force associated with specific ligands. In thisBiophysical Journal 106(6) 1258–1267
1266 Maciaszek et al.work, single-molecule AFM was employed to quantify the
response to cAMP-dependent pathway modulation via
measurement of specific ligand-receptor unbinding forces
and the CF of active adhesion receptors on the RBC.
From the perspective of cell mechanics and especially of
cell mechanics and cell adhesion modeling, our data are
significant because they can be used to set the parameters
for the simulations. Of importance, we detected the presence
of AKAPs on the membrane of both normal and SS-RBCs,
and revealed that these proteins play a significant role in the
modulation of BCAM/Lu via the cAMP pathway. Finally,
we demonstrated that HU-treatment reduces the ability for
stimulation by epinephrine suggesting that HU modifies
the b2-pathway. The study shows new, to our knowledge,
important implications for AFM cytoadhesion assays in
evaluating the pharmacologic response of adhesion recep-
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